Targeting the IPA and Matching for the Non-Inherited Maternal Antigen for Haplo-Cord Transplantation
Status:
Recruiting
Trial end date:
2023-12-01
Target enrollment:
Participant gender:
Summary
In this trial, we aim to improve the outcomes of haplo cord transplant. Haplo cord transplant
is a novel and promising way to improve transplant outcomes. We hypothesize that
identification of a graft that is at least 5/6 matched and inherited paternal antigen (IPA)
targeted (i.e., cord blood grafts share one or more IPA antigens with the prospective
recipient) is more important to the outcome of haplo cord transplant than the nucleated cell
dose. The identification of such a graft for a large proportion of the subjects may
necessitate accepting a lower umbilical cord graft dose.
In addition to a umbilical cord blood transplant, recipients will receive stem cells from a
family member ( a haplo-identical donor) . After collection and prior to infusion, these
cells will be purified using a device called a CliniMACS CD34 selection device. The subject
will undergo a chemotherapy conditioning regimen prior to transplantation. No experimental
drugs are used in this study, and the combinations of drugs that will be used in the
conditioning regimen are combinations that have been used in the past.